antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine-Seqirus-influenza

This is an experimental formulation of Seqirus's MF59-adjuvanted trivalent influenza vaccine (aTIV) designed for the elderly population (65 years and older). It features modified concentrations of both the influenza hemagglutinin antigens and the MF59 adjuvant, typically involving doubled or tripled dosages compared to the standard licensed version (FLUAD). The vaccine contains subunit antigens from two influenza A strains and one influenza B strain. The MF59 adjuvant, an oil-in-water emulsion composed of squalene, polysorbate 80, and sorbitan trioleate, is included to overcome immunosenescence by enhancing the recruitment of antigen-presenting cells and increasing the breadth and magnitude of the antibody response. A Phase 1 dosage-finding study evaluated these modified levels to optimize immunogenicity against seasonal influenza while monitoring for increased local reactogenicity.

Other names

modified aTIVadjuvanted trivalent subunit influenza vaccine (modified dosage)